enVista Envy by Bausch + Lomb approved by Health Canada

(Image Credit: AdobeStock)

Health Canada has approved the enVista Envy full visual range intraocular lens (IOL) from Bausch + Lomb Corporation. According to the company, this is the first global regulatory approval of the new lens.

Luc Bonnefoy, president, Global Surgical, Bausch + Lomb, commented on the approval in a press release from the company.¹

“enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said Bonnefoy. “This first premium IOL on the enVista platform follows the US launch of enVista Aspire late last year. The company plans to launch complementary designs to round out the well-known enVista portfolio in the coming months to better address all patient needs.”

The enVista Envy features ActivSync Optic Intelligent Energy Distribution, which optimizes vision in every lighting condition, and ClearPath technology, which helps reduce light scattering, according to Bausch + Lomb.

A multicenter, randomized, controlled clinical trial was conducted in Canada that demonstrated “excellent long-term outcomes with the enVista Envy IOL.”¹ From the trial, 93% of patients reported little to no bothersomeness for dysphotopsia, while 94% of patients reported little to no difficulty viewing close objects while delivering excellent distance vision spectacle-free post-surgery with 4 diopters of continuous visual range.¹

The enVista Envy IOL will become commercially available in Canada in mid-June, while the company is in the process of seeking regulatory approvals for the lens in the US and Europe.

References:

1. Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens. Press release; May 28, 2024. Accessed May 28, 2024. https://www.businesswire.com/news/home/20240528268272/en/Bausch-Lomb-Receives-Health-Canada-Approval-for-enVista%C2%AE-Envy%E2%84%A2*-Full-Visual-Range-Intraocular-Lens